THE WOODLANDS, Texas, May 9, 2011 /PRNewswire/ — Lexicon Pharmaceuticals, Inc.
(Nasdaq:
LXRX) announced today that it will hold its Annual R&D Day
on Thursday, May 12, 2011 from 9:00 a.m. to 12:00 p.m. Eastern Time
in New York, New York. Members of Lexicon’s senior management
team will provide in-depth reviews of the company’s clinical
programs and an overview of several other preclinical programs in
the company’s pipeline. The review of the company’s clinical
programs will include a presentation of results obtained to date
from carcinoid syndrome patients participating in the E.U.-based
open-label clinical trial of LX1032, an inhibitor of tryptophan
hydroxylase that reduces peripheral serotonin production without
affecting brain serotonin levels.
A live webcast of the event may be accessed on Lexicon’s
corporate website at www.lexpharma.com. An
archived version of the webcast will be available for 30 days after
the event on the company’s website.
About Lexicon
Lexicon is a biopharmaceutical company focused on discovering
breakthrough treatments for human disease. Lexicon currently
has four drug candidates in mid-stage development for diabetes,
irritable bowel syndrome, carcinoid syndrome and rheumatoid
arthritis, all of which were discovered by Lexicon’s research team.
Lexicon has used its proprietary gene knockout technology to
identify more than 100 promising drug targets. Lexicon has
focused drug discovery efforts on these biologically-validated
targets to create its extensive pipeline of clinical and
preclinical programs. For additional information about
Lexicon and its programs, please visit www.lexpharma.com.
Safe Harbor Statement
This press release contains “f
‘/>”/>
